NASDAQ: HCATHealth Catalyst Inc Stock
$5.60-0.43 (-7.13%)
Updated Apr 25, 2024
HCAT Price
$5.60
Fair Value Price
N/A
Market Cap
$327.95M
52 Week Low
$5.45
52 Week High
$14.37
P/E
-2.68x
P/B
0.89x
P/S
1.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$295.94M
Earnings
-$118.15M
Gross Margin
44.5%
Operating Margin
-42.88%
Profit Margin
-39.9%
Debt to Equity
0.91
Operating Cash Flow
-$33M
Beta
1.19
Next Earnings
Jun 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
HCAT Overview
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights. The company was formerly known as HQC Holdings, Inc. and changed its name to Health Catalyst, Inc. in March 2017. Health Catalyst, Inc. was founded in 2008 and is based in South Jordan, Utah.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HCAT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HCAT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HCAT is good value based on its book value relative to its share price (0.89x), compared to the US Health Information Services industry average (3.36x)
P/B vs Industry Valuation
HCAT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more HCAT due diligence checks available for Premium users.
Be the first to know about important HCAT news, forecast changes, insider trades & much more!
HCAT News
Valuation
HCAT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.68x
Industry
72.09x
Market
40.97x
HCAT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.89x
Industry
3.36x
HCAT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HCAT's financial health
Profit margin
Revenue
$75.1M
Net Income
-$30.3M
Profit Margin
-40.4%
HCAT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
HCAT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$701.8M
Liabilities
$334.9M
Debt to equity
0.91
HCAT's short-term assets ($393.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HCAT's short-term assets ($393.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HCAT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HCAT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$19.0M
Investing
$29.9M
Financing
$395.0k
HCAT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HCAT vs Health Information Service Stocks
Health Catalyst Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.